Followers | 0 |
Posts | 23 |
Boards Moderated | 0 |
Alias Born | 02/11/2021 |
Monday, February 22, 2021 10:29:44 AM
The FDA has designated Fast Track status to Celsion Corporation's (NASDAQ: CLSN) GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer.
Fast Track status provides more frequent interaction with the FDA review team and a rolling review of the marketing application.
GEN-1 is currently in Phase 2 OVATION study, which combines GEN-1 with standard-of-care neoadjuvant chemotherapy in patients newly diagnosed with Stage 3/4 ovarian cancer.
The study's primary endpoint is two show the equivalent of a 33% improvement in progression-free survival compared with the control arm (standard of care alone).
Price Action: CLSN shares rally 74.7% at $3.32 in premarket trading on the last check Monday.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM